Weekly Clinical Updates

Community-onset bacterial coinfection in children critically ill with SARS-CoV-2 infection | Risk of Coronavirus Disease 2019–Associated Pulmonary Aspergillosis Based on Corticosteroid Duration | Cardiac abnormalities in Long COVID 1-year post-SARS-CoV-2 infection | Long-term gastrointestinal outcomes of COVID-19 | Confronting the evolution and expansion of anti-vaccine activism in the USA | Effectiveness of Maternal Influenza Vaccination in Peru PRIME Cohort | Bivalent booster effectiveness against severe COVID-19 outcomes in Finland | Immunomodulators for severe coronavirus disease-2019 in transplant patients | Characteristics and predictors of persistent symptoms post-COVID-19 in children and young people | Parental Nonadherence to Health Policy Recommendations for Prevention of COVID-19 | Viral kinetics of sequential SARS-CoV-2 infections | Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population | One-Year Adverse Outcomes Among US Adults With Post–COVID-19 Condition

Fatal Fulminant Cerebral Edema in Six Children With SARS-CoV-2 Omicron BA.2 Infection in Taiwan | Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children | COVID-19 vaccines versus pediatric hospitalization | Maternal SARS-CoV-2 vaccination and infant protection against SARS-CoV-2 | Immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children | Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid | Effect of covid-19 vaccination on long covid: systematic review | FDA Authorizes First Over-the-Counter At-Home Test to Detect Both Influenza and COVID-19 Viruses | Epidemiologic Characteristics of SARS-CoV-2 Recombinant Variant XBB.1.5 | Certifying Deaths Due to Coronavirus Disease 2019

Sex differences in cardiovascular complications and mortality in hospital patients with covid-19 | Efficacy and Safety of an Ad26.RSV.preF–RSV preF Protein Vaccine in Older Adults | A third vaccine dose equalizes the levels of effectiveness | Sotrovimab retains activity against SARS-CoV-2 Omicron variant | Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients | Viral burden rebound in hospitalized patients with COVID-19 receiving oral antivirals | Serological response to vaccination in post-acute sequelae of COVID | Association of COVID-19 Vaccination With Risk for Incident Diabetes After COVID-19 Infection | Past SARS-CoV-2 infection protection against re-infection | Postacute Sequelae of SARS-CoV-2 in University Setting

Intra-Host Evolution Provides for the Continuous Emergence of SARS-CoV-2 Variants | A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273 | The political polarization of COVID-19 treatments among physicians and laypeople in the United States | Maternal mRNA covid-19 vaccination during pregnancy and delta or omicron infection or hospital admission in infants: test negative design study | SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster | The impacts of SARS-CoV-2 vaccine dose separation and targeting on the COVID-19 epidemic in England

The Negative Effect of Preexisting Immunity on Influenza Vaccine | Prior vaccination enhances immune responses during SARS-CoV-2 breakthrough infection with early activation of memory T cells | Bacillus Calmette-Guérin vaccine for prevention of COVID-19 and other respiratory tract infections in older adults | Relationship between immune response to SARS-CoV2 vaccines and development of breakthrough infection | Early Treatment with Pegylated Interferon Lambda for Covid-19 | Long-term high-dose immunoglobulin successfully treats Long COVID patients with pulmonary, neurologic, and cardiologic symptoms | Consistency of covid-19 trial preprints with published reports | Peru confirms H5N1 avian flu in marine mammals | Incidence of Chronic Spontaneous Urticaria | COVID-19 Mortality and Progress Toward Vaccinating Older Adults

Information for Persons Who Are Immunocompromised Regarding Prevention and Treatment of SARS-CoV-2 Infection | Severe Fatigue and Persistent Symptoms at Three Months Following SARS-CoV-2 Infections During the Pre-Delta, Delta, and Omicron Time Periods | Reconsideration of Antinucleocapsid IgG Antibody as a Marker of SARS-CoV-2 Infection Postvaccination for Mild COVID-19 Patients | Effectiveness of Bivalent Boosters against Severe Omicron Infection | Prevalence and Clinical Outcomes of Respiratory Syncytial Virus versus Influenza in Adults | Assessment of COVID-19 as the Underlying Cause of Death Among Children and Young People Aged 0 to 19 Years in the US | Association of culturable-virus detection and household transmission of SARS-CoV-2 – California and Tennessee, 2020–2022 | Efficacy and safety of antimicrobial stewardship prospective audit and feedback in patients